Journey Medical (DERM) Insider Md Buys 10,000 Shares

Rosenwald Lindsay Md made a move in the stock market by buying 10,000 shares of Journey Medical Corporation (NasdaqCM: DERM) on June 25, 2026. The transaction was not part of a pre-planned trading scheme.

Insider Buying and Selling at Journey Medical Corporation

Several insiders at Journey Medical Corporation, including Justin Adam Smith, Michael Cooper Pearce, Neil Herskowitz, and Rosenwald Lindsay Md, each bought 10,000 shares on June 25, 2026. Earlier, on April 22, 2026, CFO Joseph Benesch and COO Ramsey Alloush also acquired significant shares, with Benesch buying 28,907 shares and Alloush 62,795 shares.

Other Institutional Activity in Journey Medical Corporation

Wasatch Advisors LP significantly increased its position in Journey Medical by adding 817,095 shares, bringing its total to 2,133,370 shares valued at approximately $10.01 million, marking a 62.1% increase. BlackRock, Inc. also grew its position by 253,078 shares, ending with 972,862 shares valued at about $4.56 million, a 35.2% rise. Conversely, Tang Capital Management LLC reduced its holdings by 244,596 shares, now holding 1,610,000 shares worth $7.55 million, a 13.2% decrease. Vanguard Capital Management LLC opened a new position with 1,082,080 shares valued at $5.07 million.

Journey Medical Corporation Stock Down 9.4%

On Saturday, shares of Journey Medical Corporation traded around $6.62. The company has a market capitalization of approximately $182.3 million. Its forward P/E ratio is not meaningful due to negative earnings, and it has a beta of 1.097, indicating moderate volatility. The stock's 52-week range is between $4.31 and $9.56, with a 50-day moving average of $5.79 and a 200-day moving average of $7.12. The current ratio stands at 1.717, and the quick ratio is 1.38, with a debt-to-equity ratio of 82.602.

Analysts Set New Price Targets

On March 26, 2026, HC Wainwright & Co. reiterated its buy rating for Journey Medical with a price target of $13.0. The consensus among analysts is a strong buy, with an average target price of $13.5 based on four analyst opinions.

About Journey Medical Corporation

Journey Medical Corporation, headquartered in Scottsdale, Arizona, is a pharmaceutical company that develops and sells products for dermatological conditions in the U.S. Its product lineup includes treatments for conditions like acne, hyperhidrosis, and rosacea, as well as products for wound care and fungal infections. Led by CEO Claude Maraoui, the company employs 58 people.

Bottom Line

Insider buying at Journey Medical Corporation suggests confidence from its executives and board members. The company's stock has shown volatility, reflecting both insider and institutional interest. Investors often watch insider transactions as potential indicators of a company's future performance, though these trades are backward-looking and may not reflect current sentiment.